Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000330953 | SCV000336742 | likely benign | not specified | 2015-10-30 | criteria provided, single submitter | clinical testing | |
Genetic Services Laboratory, |
RCV000330953 | SCV000596311 | uncertain significance | not specified | 2016-08-08 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001855137 | SCV002171983 | uncertain significance | not provided | 2022-10-13 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 2434 of the PCNT protein (p.Leu2434Ile). This variant is present in population databases (rs112633352, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with PCNT-related conditions. ClinVar contains an entry for this variant (Variation ID: 284215). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004021155 | SCV005002899 | uncertain significance | Inborn genetic diseases | 2021-08-30 | criteria provided, single submitter | clinical testing | The c.7300C>A (p.L2434I) alteration is located in exon 33 (coding exon 33) of the PCNT gene. This alteration results from a C to A substitution at nucleotide position 7300, causing the leucine (L) at amino acid position 2434 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |